It has been demonstrated that the lack of long-term antitumor efficacy of PARP inhibitor, Olaparib, is partially attributed to its activation of Signal Transducer and Activator of Transcription 3 (STAT3) in tumors and the tumor microenvironment (5, 6). This evidence concerns the gene PARP1 and neoplasm.